hotspot -WSS

hotspot

author：fashion 2025-10-02 20:59:51 - browse：8

BiTE Bridge — Illustration of a BiTE, Amgen's bispecific antibodies Amgen

In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

“We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

WSS

Primary care physicians play key roles in Alzheimer's management

Food as medicine: Medically tailored meals may get standardized

NIH confirmation hearing shows politicization of research

STAT Summit: GSK CEO on pharma giant's new direction

FDA's naming rule on biosimilars has undermined competition

Donor acceptance rates hint at racial, gender bias in heart transplants: study

explore

hotspot

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Solve the antibiotic resistance crisis with preventive drugs

What does generative AI mean for health care? We asked experts

Solve the antibiotic resistance crisis with preventive drugs

United colonoscopy coverage change 'may cost lives,' doctors say

Why health workers in Gaza are injured or die at high rates

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The explosion of genetic testing requires a new approach

Affirmative action in medical school literally saved lives

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

focus

Lawmakers consider Medicare pay reforms for doctors

Vertex Pharmaceuticals may move headquarters in Boston

First Opinion Podcast: Long Covid needs a new approach

STAT Readout Newsletter: Today's biggest biotech updates

Primary care physicians play key roles in Alzheimer's management

Vertex Pharmaceuticals may move headquarters in Boston

leisure time

knowledge

explore

explore